THE ROLE OF MEDICAL IMAGING IN REDUCING ATTRITION IN EARLY DRUG DEVELOPMENT
The pharmaceutical industry is suffering from very low clinical success rates of approximately 11–13% for new drugs. The most common cause of failure in both Phases 2 and 3 is lack of efficacy. This seminar will explain the background to this problem and explore how medical imaging techniques can, with appropriate analysis, help improve the situation.
Speaker Fred Wilson will also explain how he has ended up leading on respiratory imaging at GlaxoSmithKline, having followed a career path that started with making components for telecommunications systems and continued via the NHS and some other roles, including visiting over 100 beauty salons in a year along the way.
Fred Wilson is Director, Clinical Imaging – Respiratory Imaging lead at GlaxoSmithKline. He is a Medical Physicist who has been working on the application of Medical Imaging and Physiological Measurements to drug development since 2008. He worked for 4 years at Pfizer (Sandwich, UK) and then as an independent consultant before joining GlaxoSmithKline (Stevenage, UK) in July 2014, where he is the clinical imaging lead for the Respiratory Therapeutic Area. Prior to joining the pharmaceutical industry he worked as a Medical Physicist in the NHS and in several other technically focussed R&D roles in other industries. He holds an MA and MSci in Natural Sciences from the University of Cambridge and an MSc in Medical Physics from the University of Exeter, and is a member of the Institute of Physics (IoP), Institute of Physics and Engineering in Medicine (IPEM), International Pharmaco-EEG Society (IPEG) and the European College of Neuropsychopharmacology (ECNP).
At GSK we are on a mission: to help people do more, feel better and live longer. For 150 years, we have helped transform the health, lives and futures of millions of people around the world.
We now have an estimated 7% share of the global pharmaceutical market and are the world’s largest over-the-counter medicines company. For more than 40 years, we have been a leader in medicines to treat respiratory diseases, and we continue to innovate in this area.
As a science-led company, we research and develop a broad range of innovative products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare.
In 2016 our turnover was £27.9 billion and we have around 100,000 people working in over 150 countries, with more than a third of these in emerging markets and over 11,000 in R&D.
Date: Tuesday, 27 February
Location: Roberts Building, G08, Sir David Davies LT (map)
18.00 – 19.00: Seminar
19.00 – 20.00: Drinks reception